Journal Mobile Options
Table of Contents
Vol. 226, No. 3, 2011
Issue release date: September 2011
Ophthalmologica 2011;226:127–137

Alpha-Lipoic Acid for the Prevention of Diabetic Macular Edema

Haritoglou C. · Gerss J. · Hammes H.P. · Kampik A. · Ulbig M.W. · for the RETIPON Study Group
aDepartment of Ophthalmology, Ludwig Maximilian University, Munich, bInstitute of Biostatistics and Clinical Research, University of Münster, Münster, and c5th Medical Department, University Hospital Mannheim, Mannheim, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Introduction: To evaluate the effect of α-lipoic acid (ALA) on the occurrence of diabetic macular edema. Methods: Randomized, double-blind, placebo-controlled, multicenter, multinational study. Patients were randomized to the treatment group with 600 mg ALA per day or the placebo group. Every 6 months stereo fundus photographs, HbA1c levels, and an ophthalmological examination were documented. The primary endpoint was the occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years. Results: We randomized 235 patients with type II diabetes mellitus into the treatment group (mean age 58.0 years) and 232 into the placebo group (mean age 57.9 years). Mean HbA1c level was 8.1, with no significant differences between the treatment (mean 8.2, SD ± 1.35) and placebo groups (mean 8.1, SD ± 1.29). HbA1c values remained constant over time. In the treatment and placebo groups, 84 and 86 patients (35.7 and 37.1%) had insulin-dependent diabetes mellitus (IDDM) with a median duration of diabetes of 9.3 versus 9.0 years in the placebo group. Visual acuity remained unchanged during the entire trial. Concerning the primary endpoint, the study provided a negative result, i.e. 26/235 patients in the treatment group and 30/232 patients in the placebo group developed CSME. Confirmatory intention-to-treat analysis of the primary endpoint revealed no statistically significant difference between groups (log-rank test, p = 0.7108, HR = 0.9057 with CI = 0.5355–1.5317). Median follow-up was identical (2.00 years). Conclusions: A daily dosage of 600 mg ALA does not prevent the occurrence of CSME in IDDM patients.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Harris MI: Diabetes in America: epidemiology and scope of the problem. Diabetes Care 1998;21(suppl 3):C11–C14.
  2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy. N Engl J Med 2000;342:381–389.
  3. Klein R, Klein BEK, Moss SE: Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984;119:54–61.
  4. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP: A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450–1452.
  5. Brownlee M: Glycation and diabetic complications. Diabetes 1994;43:836–841.
  6. Frank RN: On the pathogenesis of diabetic retinopathy. Ophthalmology 1984;91:626–634.
  7. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA: Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. Exp Eye Res 1993;57:723–735.
  8. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT: Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445–450.
  9. Bhagat N, Grigorian RA, Tutela A, Zarbin MA: Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1–32.
  10. Ishida S, Usui T, Yamashiro K, et al: VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155–2162.
  11. Du X, Matsumura T, Edelstein D, et al: Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049–1057.
  12. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–820.
  13. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–259.
  14. Mayer-Davis EJ, Bell RA, Reboussin BA, Rushing J, Marshall JA, Hamman RF: Antioxidant nutrient intake and diabetic retinopathy: the San Luis Valley Diabetes Study. Ophthalmology 1998;105:2264–2270.
  15. Hammes HP, Bartmann A, Engel L, Wülfroth P: Antioxidant treatment of experimental diabetic retinopathy with nicanartine. Diabetologia 1997;40:629–634.
  16. Lin J, Bierhaus A, Bugert P, et al: Effect of R-(+)-α-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006;49:1089–1096.
  17. Kowluru RA, Odenbach S: Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53:3233–3238.
  18. Biewenga G, Haenen GRM, Bast A: The pharmacology of the antioxidants lipoic acid. Gen Pharmac 1997;29:315–331.
  19. Jacob S, Henriksen EJ, Schiemann AL, et al: Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Drug Res 1995;45:872–874.
  20. Paasche G, Huster D, Reichenbach A: The glutathione content of retinal Müller (glial) cells: the effects of aging and of application of free-radical-scavengers. Ophthalmic Res 1998;30:351–360.
  21. Packer L, Witt EH, Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med1995;19:227–250.
  22. Packer L, Tritschler HJ, Wessel K: Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22:359–378.
  23. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid (ALADIN Study). Diabetologia 1995;38:1425–1433.
  24. Ziegler D, Greis FA: α-Lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997;46 (suppl 2):62–66.
  25. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs – an extension of the modified Arlie House Classification. EDTRS Rep No 10. Ophthalmology 1991;98:786–806.
  26. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. EDTRS Rep No 11. Ophthalmology 1991;98:807–822.
  27. Kowurlu RA, Tang J, Kern TS: Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001;50:1938–1942.
  28. Gaede P, Veldel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 Randomised Study. Lancet 1999;353:617–622.
  29. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501–1510.
  30. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425–1433
  31. Reljanovic M, Reichel G, Rett K, et al: Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha lipoic acid in diabetic neuropathy. Free Radic Res 1999;31:171–179.
  32. Ziegler D, Hanefeld M, Ruhnau KJ, et al: Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). ALADIN III Study Group. Alpha-lipoic acid in diabetic neuropathy. Diabetes Care 1999;22:1296–1301.
  33. Jacob S, Ruus P, Hermann R, et al: Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309–314.
  34. Ruhnau KJ, Meissner HP, Finn JR, et al: Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040–1043.
  35. Ametov AS, Barinov A, Dyck PJ, et al: The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003;26:770–776.
  36. Packer L, Witt EH, Tritschler HJ: Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227–250.
  37. Cremer DR, Rabeler R, Roberts A, Lynch B: Safety evaluation of alpha-lipoic acid (ALA). Regul Toxicol Pharmacol 2006;46:29–41.
  38. Ziegler D, Ametov A, Barinov A, et al: Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–2370.
  39. Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW, CALDIRET Study Group: Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009;373:1364–1371.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50